Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CCLD CareCloud	$2.41 +5.7%	$2.06	$1.14 ▼ $4.84	$96.49M	2.05	400,011 shs	315,608 shs
KOOL Cesca Therapeutics	$11.68 +0.9%	$2.78	$2.10 ▼ $7.00	$28.22M	1.07	112,188 shs	3,745 shs
LUNG Pulmonx	$2.60 +0.4%	$3.45	$2.50 ▼ $9.37	$104.27M	0.52	307,748 shs	433,765 shs
THMO ThermoGenesis		$0.00	$0.00 ▼ $0.60	$1K	1.17	5,900 shs	5 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CCLD CareCloud	+5.70%	-3.60%	+17.56%	+63.95%	+12.09%
KOOL Cesca Therapeutics	+0.90%	+2.78%	+4.83%	+13.92%	+11.49%
LUNG Pulmonx	+0.39%	-0.76%	-12.16%	-61.88%	-57.65%
THMO ThermoGenesis	0.00%	0.00%	0.00%	-66.67%	-99.95%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CCLD CareCloud	2.2369 of 5 stars	1.2	5.0	0.0	0.0	2.0	1.7	2.5
KOOL Cesca Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LUNG Pulmonx	3.2784 of 5 stars	3.3	3.0	0.0	0.0	3.3	3.3	0.6
THMO ThermoGenesis	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CCLD CareCloud	2.33	Hold	$2.50	3.73% Upside
KOOL Cesca Therapeutics	0.00	N/A	N/A	N/A
LUNG Pulmonx	2.63	Moderate Buy	$11.53	343.27% Upside
THMO ThermoGenesis	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest KOOL, THMO, CCLD, and LUNG Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/22/2025	LUNG Pulmonx	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$6.50 ➝ $4.15
5/6/2025	CCLD CareCloud	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
5/1/2025	LUNG Pulmonx	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $15.00
5/1/2025	LUNG Pulmonx	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$10.00 ➝ $9.00
5/1/2025	LUNG Pulmonx	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00 ➝ $17.00

(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CCLD CareCloud	$110.84M	0.92	$1.75 per share	1.38	$3.06 per share	0.79
KOOL Cesca Therapeutics	$9.67M	2.92	N/A	N/A	$3.11 per share	3.76
LUNG Pulmonx	$83.79M	1.25	N/A	N/A	$2.17 per share	1.20
THMO ThermoGenesis	$9.61M	0.00	N/A	N/A	($0.99) per share	0.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CCLD CareCloud	$7.85M	-$0.22	N/A	2.87	N/A	8.92%	24.08%	16.09%	8/12/2025 (Estimated)
KOOL Cesca Therapeutics	-$39.72M	-$3.60	N/A	1,167.83	N/A	-98.84%	-77.30%	-37.75%	N/A
LUNG Pulmonx	-$56.39M	-$1.44	N/A	N/A	N/A	-65.27%	-63.69%	-34.94%	7/30/2025 (Estimated)
THMO ThermoGenesis	-$17.98M	-$5.14	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest KOOL, THMO, CCLD, and LUNG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/7/2025	Q1 2025	LUNG Pulmonx	-$0.37	-$0.36	+$0.01	-$0.36	$22.03 million	$22.54 million
5/6/2025	Q1 2025	CCLD CareCloud	$0.09	$0.05	-$0.04	-$0.04	$25.94 million	$27.60 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CCLD CareCloud	N/A	N/A	N/A	N/A	N/A
KOOL Cesca Therapeutics	N/A	0.50%	N/A	N/A	N/A
LUNG Pulmonx	N/A	N/A	N/A	N/A	N/A
THMO ThermoGenesis	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CCLD CareCloud	N/A	1.69	1.65
KOOL Cesca Therapeutics	0.50	1.52	0.91
LUNG Pulmonx	0.38	4.97	4.29
THMO ThermoGenesis	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CCLD CareCloud	10.16%
KOOL Cesca Therapeutics	3.11%
LUNG Pulmonx	91.04%
THMO ThermoGenesis	5.78%

Insider Ownership

Company	Insider Ownership
CCLD CareCloud	14.70%
KOOL Cesca Therapeutics	68.90%
LUNG Pulmonx	6.80%
THMO ThermoGenesis	78.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CCLD CareCloud	3,650	42.32 million	36.10 million	Optionable
KOOL Cesca Therapeutics	53	2.42 million	N/A	Not Optionable
LUNG Pulmonx	250	40.26 million	37.52 million	Optionable
THMO ThermoGenesis	40	7.95 million	1.75 million	Not Optionable

KOOL, THMO, CCLD, and LUNG Headlines

Recent News About These Companies

The Ice Water Hack: How Aqua Sculpt Boosts Thermogenesis for Fat Loss

March 10, 2025 | globenewswire.com

Ice Water Hack: How Aqua Sculpt Improves Thermogenesis for Weight Loss

February 20, 2025 | globenewswire.com

North American Morning Briefing: Stock Futures, -2-

September 19, 2024 | morningstar.comM

Is Thermogenesis Holdings Inc Stock (THMO) a Good Investment?

August 8, 2024 | aaii.comA

ThermoGenesis Holdings (OTC:THMO) Stock Quotes, Forecast and News Summary

July 28, 2024 | benzinga.com

ThermoGenesis Holdings (OTC:THMO) Stock, Short Interest Report

July 28, 2024 | benzinga.com

Why Is ThermoGenesis (THMO) Stock Down 37% Today?

June 12, 2024 | investorplace.com

THMO Stock Earnings: ThermoGenesis Holdings Misses EPS, Misses Revenue for Q1 2024

May 17, 2024 | investorplace.com

ThermoGenesis Holdings, Inc. (NASDAQ:THMO) Is About To Turn The Corner

February 27, 2024 | finance.yahoo.com

ThermoGenesis Holdings, Inc.

January 9, 2024 | thestreet.com

ThermoGenesis Holdings Stock (NASDAQ:THMO) Dividends: History, Yield and Dates

December 16, 2023 | benzinga.com

Shareholders Will Probably Hold Off On Increasing ThermoGenesis Holdings, Inc.'s (NASDAQ:THMO) CEO Compensation For The Time Being

December 8, 2023 | finance.yahoo.com

ThermoGenesis Holdings Recent Insider Activity

November 21, 2023 | benzinga.com

ThermoGenesis Holdings, Inc.: ThermoGenesis Holdings Announces Third Quarter 2023 Financial Results and Provides Corporate Update

November 15, 2023 | finanznachrichten.de

ThermoGenesis Holdings, Inc. (NASDAQ:THMO) Q3 2023 Earnings Call Transcript

November 14, 2023 | finance.yahoo.com

ThermoGenesis Holdings Announces Third Quarter 2023 Financial Results and Provides Corporate Update

November 13, 2023 | finance.yahoo.com

ThermoGenesis Q3 Earnings Preview

November 12, 2023 | msn.com

Here's what Wall Street expects from ThermoGenesis's earnings report

November 12, 2023 | markets.businessinsider.com

ThermoGenesis Holdings Inc THMO

November 12, 2023 | morningstar.comM

ThermoGenesis Holdings Earnings Preview

November 10, 2023 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KOOL, THMO, CCLD, and LUNG Company Descriptions

CareCloud NASDAQ:CCLD

$2.41 +0.13 (+5.70%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$2.37 -0.04 (-1.87%)

As of 06/27/2025 07:06 PM Eastern

CareCloud, Inc., a healthcare information technology (IT) company, provides a suite of cloud-based solutions and related business services to healthcare providers and hospitals primarily in the United States. It operates in two segments, Healthcare IT and Medical Practice Management. The company's portfolio of proprietary software and business services includes technology-enabled business solutions; cloud-based software; digital health services; healthcare IT professional services and staffing; and medical practice management services. Its technology-enabled business solutions comprise revenue cycle management services, healthcare claims clearinghouse, and medical coding and credentialing services; electronic health records, practice management software and related capabilities, patient experience management solutions, business intelligence and healthcare analytics platforms, and customized applications, interfaces, and various other technology solutions, as well as artificial intelligence, such as CareCloud cirrusAI, AI-powered clinical decision support, AI-powered virtual support assistant, AI-driven appeals, and CareCloud cirrusAI. In addition, the company provides chronic care management, remote patient monitoring, and telemedicine solutions; and professional and consulting services, workforce augmentation and on-demand staffing, and strategic advisory services. Further, it offers medical practice management services to medical practices comprising appropriate facilities, equipment, supplies, support services, nurses, and administrative support staff, as well as management, bill-paying, and financial advisory services. It serves physicians, nurses, nurse practitioners, physician assistants, and other clinicians that render bills for their services. The company was formerly known as MTBC, Inc. and changed its name to CareCloud, Inc. in March 2021. CareCloud, Inc. was founded in 1999 and is headquartered in Somerset, New Jersey.

Cesca Therapeutics NASDAQ:KOOL

Cesca Therapeutics Inc. develops, commercializes, and markets a range of automated technologies and products for cell-based therapeutics in the United States, China, rest of Asia, Europe, and internationally. The company develops automated blood and bone marrow processing systems that enable the separation, processing, and preservation of cell and tissue therapy products. It offers AutoXpress System, a proprietary automated device and companion sterile disposable for concentrating hematopoietic stem cells from cord blood; Point-of-CareXpress System, a proprietary automated device and companion sterile disposable for the isolation and concentration of hematopoietic stem cells from bone marrow; CAR-TXpress System, a suite of multi-component automated system that allows the automated manufacturing, expansion, and storage of cellular therapies for immuno-oncology; BioArchive System, an automated cryogenic device for single-cassette based cryo-storage of biological license applications products; and manual bag sets for use in the processing and cryogenic storage of cord blood. The company is also developing autologous stem cell-based therapies that address medical needs for applications in the vascular, cardiology, and orthopedic markets. In addition, it provides cell manufacturing and banking services. The company was formerly known as ThermoGenesis Corp. and changed its name to Cesca Therapeutics Inc. in February 2014. Cesca Therapeutics Inc. was founded in 1986 and is headquartered in Rancho Cordova, California. Cesca Therapeutics Inc. is a subsidiary of Boyalife (Hong Kong) Limited.

Pulmonx NASDAQ:LUNG

$2.60 +0.01 (+0.39%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$2.54 -0.06 (-2.31%)

As of 06/27/2025 06:35 PM Eastern

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

ThermoGenesis NASDAQ:THMO

ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics in the United States, China, the United Arab Emirates, Vietnam, and internationally. The company provides medical device products for automated cell processing. Its clinical bio-banking applications include AXP II Automated Cell Separation System, an automated fully closed cell separation system for isolating stem and progenitor cells from umbilical cord blood; and BioArchive Automated Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications. The company's point-of-care applications include XP Point-of-Care System, an automated, fully closed, sterile system that allows for the rapid and automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells at the point-of-care, such as surgical centers or clinics; and PXP-1000 System, an automated, fully closed system that provides fast, reproducible separation of multiple cellular components from blood with minimal red blood cell contamination. Its cell processing products comprise X-Series products for general laboratory use, such as X-Lab for cell isolation, X-Wash System for cell washing and reformulation, and X-Mini for high efficiency small scale cell purification. The company also provides contract development and manufacturing services for cell and cell-based gene therapies. It markets and sells its medical device products through independent distributors, as well as direct to end-user customers. The company was formerly known as Cesca Therapeutics Inc. and changed its name to ThermoGenesis Holdings, Inc. in November 2019. ThermoGenesis Holdings, Inc. was incorporated in 1986 and is headquartered in Rancho Cordova, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time